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A  diverse  community  of  clinical  geneticists,  molecular 
biologists,  cytogeneticists,  genomicists,  and  computa­
tional biologists gathered at the Wellcome Trust Genome 
Campus (Hinxton, UK) for the ‘Genomic Disorders 2011’ 
meeting, organized by Nigel Carter and Matthew Hurles 
(Wellcome  Trust  Sanger  Institute,  UK),  Helen  Firth 
(Cambridge  University,  UK),  and  Jim  Lupski  (Baylor 
College of Medicine, USA). This year, it spotlighted the 
emergence  of  the  genomics  of  rare  diseases.  Sessions 
discussed  discovery  efforts  targeted  at  rare  Mendelian 
and complex diseases, how this genetic information affects 
treatment and therapeutic options, and the challen  ges for 
clinical  genetics  coupled  with  the  arrival  of  affordable 
‘­omics’  technologies.  In  this  report  we  cover  some 
highlights of this exciting and timely meeting, focusing 
on new approaches impacting the study of rare diseases, 
and hopes and challenges attending their application to 
clinical genetics.
The genetics of rare diseases
Rare  diseases,  defined  as  affecting  fewer  than  200,000 
people,  encompass  over  7,000  recognized  entities.  In 
aggregate they comprise about 10% of the total disease 
burden  of  humanity,  and  they  are  far  from  being  rare 
(http://www.genome.gov). Rare diseases have classically 
been viewed as the domain of Mendelian genetics ­ single 
gene disorders with clear evidence of dominant, reces­
sive, or sex­linked patterns of recurrence in families. As 
of  mid­April  2011,  mutations  in  2,565  genes  causing 
4,321 disorders were cataloged in the Online Mendelian 
Inheritance in Man (http://www.omim.org). The associated 
phenotypes  involve  every  organ  system,  and  include 
Hirschsprung disease, α­thalassemia/mental retarda  tion 
syndrome, skeletal dysplasias, ciliopathy syndromes, and 
a diverse collection of neurologic syndromes, to mention 
several for which recent research was highlighted at the 
meeting. Each genotype­phenotype connection made has 
provided  a  unique  opportunity  for  insight  into  human 
physiology and pathophysiology. However, these known 
cases  are  only  the  tip  of  an  emerging  iceberg  since 
thousands of additional described phenotypes exist with 
as yet unknown underlying mutation(s).
Rare versus common diseases
Our recent approach to rare diseases ­ centered on the 
search for single gene etiologies ­ stands in contrast to 
that of common disorders. Common disorders have been 
modeled as more dependent on multiple modifying genes 
and environmental factors and more complex etiologies 
in heritable risk. The idea that common genetic variants 
may  be  important  thrusts  common  diseases  into  the 
forefront of genomic applications with the availability of 
genome­wide  SNP  maps.  Genome­wide  association 
studies have leveraged impressive genomic­scale methods 
and  large  numbers  of  cases  and  controls  to  identify 
important loci involved in disease susceptibility and trait 
variation.
However,  this  dichotomy  between  common  and  rare 
diseases is simplistic and has perhaps been over  empha­
sized.  It  is  now  widely  acknowledged  that  common 
genetic variants conferring large effects are not routinely 
found  by  association  studies,  and  rare  genetic  variants 
are  gaining  credibility  as  important  contributors  to 
common  diseases.  This  was  a  central  topic  at  this 
meeting.  Such  rare  variants  can  be  minute  sequence 
changes  or  structural  variants;  mechanisms  underlying 
the latter, including copy number variants (CNVs), and 
high copy number repeat insertions (retrotransposons), 
were  described  by  James  Lupski  and  John  Moran 
(University of Michigan, USA), respectively. The meeting 
also highlighted CNVs being sought in many intensively 
studied ‘common’ disorders. For example, Pamela Sklar 
(Mount  Sinai  School  of  Medicine,  USA)  and  Nigel 
Williams (Cardiff University, UK) presented in a session 
devoted to neuropsychiatric disorders, including schizo­
phrenia and autism, and Heather Mefford (University of 
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to characterizing phenotypes and genotypes in epilepsy.
Rare  variants  are  certainly  potential  culprits  in  these 
diseases. Thus, a common phenotype may well be a collec­
tion  of  rare  genetic  diseases  masquerading  as  a  single 
clinical entity. It is important to note that the definition of 
‘common’ is arbitrary and that autism and other disorders 
considered common are much less frequent than major 
chronic diseases such as diabetes or hypertension.
Genetic interactions in rare disease genetics
Conversely, there is no reason to assert that rare diseases 
will be totally explicable by mutations in single genes or 
rare variants. For example, common polymorphisms are 
known  to  affect  susceptibility  to  Hirschsprung  disease 
and cleft lip/palate. It is foreseeable that as genomic tools 
are  applied  to  rare  diseases  en  masse,  the  primarily 
Mendelian  acting  lesions  will  become  evident  earliest. 
Our  collective  experiences  should  establish  the  true 
burden of these types of mutations on human health, and 
this will certainly be important. What is scientifically as 
exciting  is  that  hypotheses  surrounding  more  complex 
segregation models for the basis of genetic disease may 
now become testable.
Molecular methods development has been inseparable 
from the types of ideas that we can approach experi  men­
tally. Historically, this has meant we go to the laboratory 
bench enabled to address increasingly fundamental ques­
tions. Paradoxically, as our methods are now supersized 
to the ­omics scale, we are in the position of being able to 
survey the genome hypothesis­free. If thinking about the 
genetic basis of a disease used to go hand in hand with 
the  clinical  history  and  physical  examination,  our 
standard  starting  point  may  soon  include  the  patient’s 
sequenced genome.
Personal genomics and the potential of clinical 
researchers
This  newfound  relevance  of  genomics  to  an  individual 
patient case cannot be understated. Our historic needs 
for large kindreds to refine the relevant genetic interval 
and  cumbersome  analyses  for  positional  cloning  have 
limited the diseases amenable to study. It is a tremen­
dously  exciting  prospect  that  an  astute  clinician  and  a 
single memorable patient can now become the critical 
participants  in  identifying  the  fundamental  molecular 
defect in that individual. Our ability to sequence DNA in 
many ways has defined genetics. We believe our ability to 
massively  parallel  sequence  genomes  will  be  credited 
with a massive paralleling of clinical genetics investi  ga­
tions. And we expect great progress as the field opens to 
a great plurality of research purposes.
So what does one clinician or a small research team do 
with  all  these  sequences?  That  we  have  a  lot  to  learn 
about  managing  the  datasets  that  genomic  methods 
provide was a recurring theme in Hinxton. Fundamental 
questions include how to grasp and incorporate the spec­
trum of human genetic diversity in searches for causative 
variants  and  how  to  predict  causality  from  among  the 
large  numbers  of  candidate  variants.  Aspects  of  these 
challenges  were  discussed  by  Daniel  MacArthur  and 
Matt  Hurles  (Wellcome  Trust  Sanger  Institute,  UK), 
Shamil Sunyaev (Brigham and Women’s Hospital, USA), 
and  Dominik  Seelow  (Charité  University  Hospital, 
Germany).  The  need  to  intelligently  filter  information 
cannot be understated and is still a developing art.
The International Rare Disease Research Consortium
While  the  advent  of  accessible  genomic  technologies 
presents huge advantages for studying the genetic basis 
of  disease  in  an  individual,  case­by­case  genomics  will 
not then be without an infrastructure. The complexities 
of sequence analysis and the incidence of rare diseases 
will continue to challenge us to collaborate in unprece­
dented ways. Sharing information about polymorphisms 
will likely be paramount to our understanding of genetic 
variation. Differentiating disease causing mutations from 
irrelevant genetic variants will be facilitated through use 
of shared data sets on unaffected individuals. Establishing 
centralized repositories that minimize work for contri  bu­
tors,  simplify  accessibility  for  researchers,  and  protect 
patient  interests  will  be  important.  The  recently 
announced International Rare Disease Research Consor­
tium between the US National Institutes of Health and 
the European Commission should further these goals and 
hopefully  will  be  a  truly  international  investment  and 
resource.  It  was  described  for  meeting  attendants  by 
Jacques Remacle (European Commission, Belgium).
Conclusions
Those with an interest in the genetics of rare diseases 
stand to gain a lot in the coming years. Certainly we can 
hope for a more complete picture of etiology as multiple 
genetic  variants  are  implicated  in  related  phenotypes. 
Also,  presumably,  an  expanding  catalog  of  the  genetic 
bases of disease will show examples of biological inter­
relatedness  between  phenotypically  disparate  diseases. 
Collectively, studies should ultimately reveal how many 
of  our  total  complement  of  genes  determine  postnatal 
phenotypes. Finally, the increasing production of genome 
sequences  should  provide  the  most  complete,  direct 
measure  ments  of  the  mutation  rates  in  our  genomes. 
This may allow for a better understanding of the mecha­
nisms of mutation, giving us an unprecedented ability to 
decipher in which cells, and with what tempo, specific 
types  of  mutations  occur.  Perhaps  identification  of 
‘mutator  phenotypes’  and  an  understanding  of  their 
genetic influences can be envisioned.
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blurred  in  the  minds  of  many,  although  it  is  the 
intellectual basis of genetics that makes genomics tech­
nology  meaningful.  The  congress  of  the  two  affords 
advantages and presents challenges. With new tools, we 
can  work  relatively  unfettered  from  the  need  for  large 
family trees to reveal genes of importance and the biases 
of candidate gene approaches. However, our need for the 
gigabytes to yield biological stories, unifying explanations 
of disease, and ways to meaningfully intervene clinically 
will be strong. New conceptual frameworks for leveraging 
these high­throughput tools will be needed. It is, after all, 
getting  complicated.  Still,  we  depart  from  ‘Genomic 
Disorders 2011’ with an optimism that in the billions of 
base pairs each of us will learn to recognize our devil in 
the details.
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